Two-Pronged attack: new cell therapy aims to outsmart resistant blood cancers
NCT ID NCT04186520
Summary
This study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may help prevent the cancer from escaping treatment. Researchers will assess the safety of the therapy and how well it works for various cancers, including lymphomas and leukemias, while also testing different ways to manufacture the treatment cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin and Froedtert Hospital
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.